Neurotrack

Neurotrack is a neurotechnology company headquartered in Redwood City that has pioneered an innovative eye-tracking cognitive assessment platform designed to detect early signs of Alzheimer's disease and cognitive decline. The company's proprietary technology leverages standard webcam hardware to measure eye movement patterns and gaze behavior, translating this biometric data into precise cognitive health insights. By making advanced neurological assessment accessible through everyday devices, Neurotrack has democratized early detection of neurodegenerative conditions that typically require expensive clinical equipment and specialized settings.

The company has established itself as a significant player in the cognitive health space, having secured Series C funding of $22 million to fuel its expansion and product development. Neurotrack's digital platform serves a dual purpose, supporting both clinical research initiatives and direct-to-consumer brain health monitoring, positioning the company at the intersection of medical validation and consumer wellness. This dual-market approach has enabled the company to build credibility within the healthcare research community while scaling accessibility for individuals seeking proactive cognitive health management.

Neurotrack's innovation represents a transformative advancement in the neurotech industry by combining affordability, accessibility, and clinical validity in early cognitive decline detection. Early detection of Alzheimer's disease remains one of healthcare's most pressing challenges, as current diagnostic methods often catch the disease too late for preventive interventions, making Neurotrack's solution particularly valuable. By enabling scalable, non-invasive cognitive assessment through consumer-grade technology, the company is helping to shift the paradigm toward earlier identification and intervention, potentially extending quality of life for millions of people at risk for neurodegenerative diseases.